Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.59 |
| ▸ | ADH1C | P00326 | 1/20 | 0.59 |
| ▸ | ADH1A | P07327 | 1/20 | 0.59 |
| ▸ | ADH7 | P40394 | 1/20 | 0.59 |
| ▸ | MC5R | P33032 | 4/20 | 0.56 |
| ▸ | MC4R | P32245 | 3/20 | 0.56 |
| ▸ | MC3R | P41968 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL761211 | 0.81 | CA12 (0.49) | MC5RMC4RMC3RCYP1A2CYP2A6 | |
| SCHEMBL4672721 | 0.81 | ADH1B (0.46) | ADH1BADH1CADH1AADH7MC5R | |
| SCHEMBL6008141 | 0.81 | MC5R (0.71) | MC5RMC4RMC3RMAPK1CYP1A2 | |
| SCHEMBL24060221 | 0.79 | MC5R (0.50) | MC5RMC4RMC3RMAPK1CYP1A2 | |
| SCHEMBL8750958 | 0.77 | ADH1B (0.71) | ADH1BADH1CADH1AADH7 | |
| SCHEMBL28168169 | 0.77 | MC5R (0.51) | MC5RMC4RMC3RMAPK1CYP1A2 | |
| SCHEMBL8763196 | 0.76 | ADH1B (0.76) | ADH1BADH1CADH1AADH7 | |
| SCHEMBL4017226 | 0.76 | MC5R (0.65) | MC5RMC4RMC3RMAPK1CYP1A2 | |
| SCHEMBL720558 | 0.75 | CYP1A2 (0.56) | MC5RMC4RMC3RMAPK1CYP1A2 | |
| SCHEMBL29955760 | 0.75 | CYP1A2 (0.56) | MC5RMC4RMC3RMAPK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577377-B2 | Substituted cyclopenta pyrimidine bicyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2020-03-03 | — | — | US | disclosed |
| EP-2797603-B1 | APTAMERS AND DIAGNOSTIC METHODS FOR DETECTING THE EGF RECEPTOR | SOMALOGIC INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2018-07-10 | — | — | US | disclosed |
| EP-3335714-A1 | APTAMERS AND DIAGNOSTIC METHODS FOR DETECTING THE EGF RECEPTOR | Quest Diagnostics Investments Incorporated (US) | 2018-06-20 | — | — | EP | disclosed |
| US-20180118695-A1 | Substituted Cyclopenta Pyrimidine Bicyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2018-05-03 | — | — | US | disclosed |
| EP-2798085-B1 | APTAMERS AND DIAGNOSTIC METHODS FOR DETECTING THE EGF RECEPTOR | QUEST DIAGNOSTICS INVEST INC (US) | 2018-01-24 | — | — | EP | disclosed |
| US-9651556-B2 | Aptamers and diagnostic methods for detecting the EGF receptor | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED (US) | 2017-05-16 | — | — | US | disclosed |
| EP-2683729-B1 | APTAMERS FOR CLOSTRIDIUM DIFFICILE DIAGNOSTICS | SOMALOGIC INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-9624178-B2 | Substituted cyclopenta pyrimidine bicyclic compounds having antitmitotic and/or antitumor activity methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2017-04-18 | — | — | US | disclosed |
| US-9316647-B2 | Aptamers and diagnostic methods for detecting the EGF receptor | SOMALOGIC, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-6121282-A | 3-(CARBOXY, AMIDO, CYANO, OR HYDROXYAMINOCARBONYL)-6 OR 7-SUBSTITUTED-1,2,3,4-TETRAHYDROISOQUINOLINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2000-09-19 | — | — | US | disclosed |
| EP-1019378-A1 | HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 2000-07-19 | — | — | EP | disclosed |
| US-6040289-A | ACTIVE DRUG TREATING OBESITY | DR. KARL THOMAE GMBH (DE) | 2000-03-21 | — | — | US | disclosed |
| US-5962530-A | NEUROPEPTIDE Y ANTAGONIST | DR. KARL THOMAE GMBH (DE) | 1999-10-05 | — | — | US | disclosed |
| EP-0925063-A1 | HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-06-30 | — | — | EP | disclosed |
| WO-1998000137-A1 | HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1998-01-08 | — | — | WO | disclosed |
| WO-1998000403-A1 | HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1998-01-08 | — | — | WO | disclosed |
| US-5688823-A | ANTILIPEMIC AGENTS, ANTIGLYCEMIC AGENTS, OBESITY, GLUCOSE TOLERANCE INSUFFICIENCY, INSULIN RESISTANCE AND DIABETIC COMPLICATIONS | SANKYO COMPANY, LIMITED (JP) | 1997-11-18 | — | — | US | disclosed |
| US-5578620-A | TREATMENT OF DIABETES AND HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 1996-11-26 | — | — | US | disclosed |
| EP-0678511-A2 | Thiazolidine and oxazolidine derivatives, their preparation and their medical use | SANKYO COMPANY LIMITED (JP) | 1995-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577377-B2 | Substituted cyclopenta pyrimidine bicyclic compounds having antimitotic and/or antitumor activity and methods of use thereof | ABCG2, ABCB1, ABCC1 | ADH1B 2562/4885ADH1C 3661/4885ADH1A 3984/4885 |
| US-20180118695-A1 | Substituted Cyclopenta Pyrimidine Bicyclic Compounds Having Antimitotic and/or Antitumor Activity and Methods of Use Thereof | ABCG2, ABCB1, ABCC1 | ADH1B 2562/4885ADH1C 3661/4885ADH1A 3984/4885 |
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | CTSE, CTSB, CTSS | ADH1B 4135/4885ADH1C 2989/4885ADH1A 4125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.